Morgan Stanley Portage Biotech Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Portage Biotech Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,000 shares of PRTG stock, worth $420. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,000

Previous 1,598 25.16%

Holding current value

$420

Previous $2,000 50.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.41 - $1.89 $164 - $759	402 Added 25.16%	2,000 $1,000
Q4 2023 Feb 13, 2024	SELL	$1.09 - $2.65 $1,169 - $2,843	-1,073 Reduced 40.17%	1,598 $2,000
Q3 2023 Nov 15, 2023	SELL	$2.09 - $3.68 $1,544 - $2,719	-739 Reduced 21.67%	2,671 $5,000
Q1 2023 May 15, 2023	SELL	$2.6 - $7.2 $41 - $115	-16 Reduced 0.47%	3,410 $10,000
Q4 2022 Feb 14, 2023	SELL	$4.42 - $7.44 $888 - $1,495	-201 Reduced 5.54%	3,426 $18,000

Q3 2022 Nov 14, 2022	SELL	$6.81 - $10.12 $30,808 - $45,782	-4,524 Reduced 55.5%	3,627 $25,000
Q2 2022 Oct 27, 2022	BUY	$5.16 - $11.95 $20,154 - $46,676	3,906 Added 92.01%	8,151 $56,000
Q2 2022 Aug 15, 2022	BUY	$5.16 - $11.95 $20,154 - $46,676	3,906 Added 92.01%	8,151 $56,000
Q1 2022 Oct 27, 2022	SELL	$6.57 - $12.0 $25,662 - $46,872	-3,906 Reduced 47.92%	4,245 $27,000
Q1 2022 May 13, 2022	SELL	$6.57 - $12.0 $4,309 - $7,872	-656 Reduced 13.39%	4,245 $27,000
Q4 2021 Feb 14, 2022	BUY	$10.73 - $23.74 $3,894 - $8,617	363 Added 8.0%	4,901 $54,000
Q3 2021 Nov 15, 2021	BUY	$13.65 - $22.4 $61,943 - $101,651	4,538 New	4,538 $93,000

Others Institutions Holding PRTG

# of Institutions

Shares Held

2.16M

Call Options Held

Put Options Held

View Full List

About PORTAGE BIOTECH INC.

Ticker PRTG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,943,700
Market Cap $3.56M
Description
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a smal...

More about PRTG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account